Profound Medical (TSE:PRN - Get Free Report) is set to post its quarterly earnings results after the market closes on Thursday, November 7th. Analysts expect Profound Medical to post earnings of C($0.42) per share for the quarter.
Profound Medical (TSE:PRN - Get Free Report) last released its quarterly earnings data on Thursday, August 8th. The company reported C($0.38) earnings per share for the quarter, meeting the consensus estimate of C($0.38). The company had revenue of C$3.06 million for the quarter, compared to analysts' expectations of C$3.42 million.
Profound Medical Stock Performance
PRN stock traded down C$0.21 on Thursday, hitting C$10.18. The company had a trading volume of 1,400 shares, compared to its average volume of 7,035. The company has a current ratio of 8.61, a quick ratio of 14.98 and a debt-to-equity ratio of 16.95. Profound Medical has a 12-month low of C$9.55 and a 12-month high of C$16.00. The stock has a market cap of C$249.21 million, a price-to-earnings ratio of -6.08 and a beta of 0.81. The stock's 50-day simple moving average is C$10.97 and its 200 day simple moving average is C$11.52.
Insider Transactions at Profound Medical
In other news, Senior Officer Rashed Osman Dewan purchased 9,765 shares of the business's stock in a transaction on Thursday, August 15th. The stock was acquired at an average cost of C$12.85 per share, for a total transaction of C$125,480.25. Company insiders own 8.62% of the company's stock.
About Profound Medical
(
Get Free Report)
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.
Featured Articles
Before you consider Profound Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Profound Medical wasn't on the list.
While Profound Medical currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
